FibroGen secured regulatory approvals for roxadustat in China and Europe, but the FDA rejected the drug and asked for another clinical trial. By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially resuming development of roxadustat in another indication.
FibroGen drug pamrevlumab has failed a Phase 3 study testing it in the chronic lung disorder idiopathic pulmonary fibrosis. It’s the second trial failure for the drug in the past month and the company’s third Phase 3 failure in the past two months.
Mark Schoenebaum, a widely respected sell-side equity research analyst who most recently worked with Evercore ISI, and FibroGen CEO Thomas Neff, died during the weekend.
Being first isn’t the only goal in the drug-development business. Sometimes, an unmet patient need is so great, companies that are second or third to market stand a good chance of success. That’s what Akebia Therapeutics Inc. near Cincinnati is hoping for as it prepares to do Phase 2 clinical trials of its drug to […]